Goshonoside F5CAS# 90851-28-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 90851-28-8 | SDF | Download SDF |
| PubChem ID | 13855771 | Appearance | Powder |
| Formula | C32H54O13 | M.Wt | 646.77 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,3R,4S,5S,6R)-2-[(E)-5-[(1R,4aS,5S,6R,8aS)-6-hydroxy-5,8a-dimethyl-2-methylidene-5-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(=CCOC1C(C(C(C(O1)CO)O)O)O)CCC2C(=C)CCC3C2(CCC(C3(C)COC4C(C(C(C(O4)CO)O)O)O)O)C | ||
| Standard InChIKey | QIOMMMCQFIBVKA-PPQBIMEKSA-N | ||
| Standard InChI | InChI=1S/C32H54O13/c1-16(10-12-42-29-27(40)25(38)23(36)19(13-33)44-29)5-7-18-17(2)6-8-21-31(18,3)11-9-22(35)32(21,4)15-43-30-28(41)26(39)24(37)20(14-34)45-30/h10,18-30,33-41H,2,5-9,11-15H2,1,3-4H3/b16-10+/t18-,19-,20-,21+,22-,23-,24-,25+,26+,27-,28-,29-,30-,31+,32-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Goshonoside F5 has anti-inflammatory activity, it significantly inhibits the pro-inflammatory response induced by LPS, both in vitro and in vivo. |
| Targets | NO | PGE | NOS | COX | p65 | NF-kB | IkB | JNK | TNF-α | p38MAPK | IKK |
Goshonoside F5 Dilution Calculator
Goshonoside F5 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5461 mL | 7.7307 mL | 15.4614 mL | 30.9229 mL | 38.6536 mL |
| 5 mM | 0.3092 mL | 1.5461 mL | 3.0923 mL | 6.1846 mL | 7.7307 mL |
| 10 mM | 0.1546 mL | 0.7731 mL | 1.5461 mL | 3.0923 mL | 3.8654 mL |
| 50 mM | 0.0309 mL | 0.1546 mL | 0.3092 mL | 0.6185 mL | 0.7731 mL |
| 100 mM | 0.0155 mL | 0.0773 mL | 0.1546 mL | 0.3092 mL | 0.3865 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Goshonoside F1
Catalog No.:BCN6444
CAS No.:90851-24-4
- Cyclo(Ile-Ala)
Catalog No.:BCN2429
CAS No.:90821-99-1
- PF-04929113 (SNX-5422)
Catalog No.:BCC2130
CAS No.:908115-27-5
- SNX-2112
Catalog No.:BCC2132
CAS No.:908112-43-6
- 6,8-Di-O-methylcitreoisocoumarin
Catalog No.:BCN7380
CAS No.:908098-80-6
- Atosiban
Catalog No.:BCC5314
CAS No.:90779-69-4
- Musellactone
Catalog No.:BCN7183
CAS No.:907583-51-1
- (S)-4-Benzyl-2-oxazolidinone
Catalog No.:BCC8401
CAS No.:90719-32-7
- Ethyl beta-carboline-1-propionate
Catalog No.:BCN1311
CAS No.:90686-24-1
- 5-Hydroxysophoranone
Catalog No.:BCN6842
CAS No.:90686-12-7
- Methyl 1,4-bisglucosyloxy-3-prenyl-2-naphthoate
Catalog No.:BCN7597
CAS No.:90685-26-0
- SCH 546738
Catalog No.:BCC4110
CAS No.:906805-42-3
- ent-Labda-8(17),13E-diene-3beta,15,18-triol
Catalog No.:BCN7662
CAS No.:90851-50-6
- Ptelatoside B
Catalog No.:BCN4451
CAS No.:90852-99-6
- Aprotinin
Catalog No.:BCC1220
CAS No.:9087-70-1
- α-helical CRF 9-41
Catalog No.:BCC5727
CAS No.:90880-23-2
- M871
Catalog No.:BCC5930
CAS No.:908844-75-7
- Broussonin E
Catalog No.:BCN4452
CAS No.:90902-21-9
- Erythrocentauric acid
Catalog No.:BCN7683
CAS No.:90921-13-4
- Cl-HIBO
Catalog No.:BCC7147
CAS No.:909400-43-7
- α-CGRP (human)
Catalog No.:BCC5962
CAS No.:90954-53-3
- W146
Catalog No.:BCC7723
CAS No.:909725-61-7
- A 83-01
Catalog No.:BCC1319
CAS No.:909910-43-6
- 8-Methoxybonducellin
Catalog No.:BCN4453
CAS No.:90996-27-3
Suppression of nuclear factor-kappa B and mitogen-activated protein kinase signalling pathways by goshonoside-F5 extracted from Rubi Fructus.[Pubmed:25523460]
Int Immunopharmacol. 2015 Feb;24(2):182-190.
Rubi Fructus, a traditional Chinese medicine, was considered as an anti-inflammatory agent in folk medicine. In the present study, we investigated the signalling pathways involved in the anti-inflammatory effects of goshonoside-F5 (GF5), isolated from Rubi Fructus, in peritoneal macrophages and examined its therapeutic effect in a mouse endotoxic shock model. GF5 decreased NO and PGE2 production in LPS-stimulated macrophages (IC50=3.84 and 3.16muM). This effect involved the suppression of NOS-2 and COX-2 gene expression at the transcriptional level. Examination of the effects of GF5 on NF-kappaB signalling demonstrated that it inhibits the phosphorylation of IkappaB-alpha and IkappaB-beta, blocking their degradation and the nuclear translocation of the NF-kappaB p65 subunit. Moreover, inhibition of MAPK signalling was also observed, and phosphorylation of p38 and JNK was suppressed in the presence of GF5. Inflammatory cytokines, including IL-6 and TNF-alpha, were down-regulated by this compound after activation with LPS (IC50=17.04 and 4.09muM). Additionally, GF5 (30 and 90mg/kg, i.p.) significantly reduced the circulating cytokine levels (IL-6 and TNF-alpha) and increased survival in a mouse model of endotoxemia. These results show that GF5 significantly inhibits the pro-inflammatory response induced by LPS, both in vitro and in vivo. Our results provide a strong pharmacological basis for further understanding the potential therapeutic role of GF5 in inflammatory disease and shed new light on the bioactivity of ent-labdane diterpene glucoside.
